NIAID & Partners to Develop Antibody-Based Products for HIV Prevention NIAID and IAVI, a nonprofit scientific research organization, recently announced a collaboration to develop combinations of HIV broadly neutralizing antibodies that could be produced on a large scale at low cost to prevent and possibly treat HIV. This initiative also will leverage IAVI's existing partnership with the Serum Institute of India Pvt. Ltd. to develop an affordable and globally accessible antibody-based HIV prevention product. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107